1. CK2 blockade alleviates liver fibrosis by suppressing activation of hepatic stellate cells via the Hedgehog pathway
- Author
-
Junfu Fan, Gaozan Tong, Xixi Chen, Santie Li, Ying Yu, Shunan Zhu, Kunxuan Zhu, Zijing Hu, Yonggan Dong, Rui Chen, Junjie Zhu, Wenjie Gong, Zhicheng Hu, Bin Zhou, Yiming Chen, Litai Jin, and Weitao Cong
- Subjects
Pharmacology - Abstract
Liver fibrosis is a serious cause of morbidity and mortality worldwide characterized by accumulation of extracellular matrix produced by hepatic stellate cells (HSCs). The protein kinase CK2 is a pro-survival kinase overexpressed in human tumours. However, the biological role of CK2 in liver fibrosis is largely unknown. We aimed to investigate the mechanism by which CK2 promotes liver fibrosis.In vitro, LX-2 cells were stimulated with transforming growth factor-β (TGF-β). HSCs were also isolated for research. In vivo, the adeno-associated virus AAV-sh-csnk2a1 was used to knockdown CK2α specifically in HSCs, and CX-4945 was used to pharmacologically inhibit the enzymatic activity of CK2 in murine models of fibrosis induced by carbon tetrachloride (CClHSC-specific genetic invalidation of CK2α or pharmacological inhibition of CK2 protected mice treated with CClCK2 activation is critical to sustain the activated and fibrogenic phenotype of HSCs via SMO stabilization. Therefore, inactivation of CK2 by CX-4945 may be of therapeutic interest for liver fibrotic diseases.
- Published
- 2022